{"id":"W4402135000","doi":"10.1093/eurheartj/ehae614","title":"Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial","year":2024,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta Hospital; Canadian VIGOUR Centre; Alberta Hospital Edmonton; Health Sciences Centre; University Health Network; St. Michael's Hospital","funders":"American Regent; Genentech; U.S. Food and Drug Administration; Sanofi Australia; MicroPort; Idorsia Pharmaceuticals; Novo Nordisk; Akebia Therapeutics; Bristol-Myers Squibb; Cleveland Clinic; CryoLife; Janssen Scientific Affairs; AstraZeneca; Amarin Corporation; XBiotech; ReCor Medical; Intarcia Therapeutics; National Institutes of Health; Regeneron Pharmaceuticals; Boston Scientific Corporation; Daiichi Sankyo Europe; Servier; Gilead Sciences; Duke Clinical Research Institute; FibroGen; Esperion Therapeutics; Alnylam Pharmaceuticals; Kowa Company; Sanofi; HLS Therapeutics; Conselho Nacional de Desenvolvimento Científico e Tecnológico; GlaxoSmithKline; Amgen; York University; Moderna; Pfizer; CSL Behring; Jewish General Hospital; Bayer Corporation; Daiichi-Sankyo; AtriCure; Eli Lilly and Company","keywords":"Medicine; Myocardial infarction; Ldl cholesterol; Internal medicine; Apolipoprotein B; Cholesterol; Cardiology; Baseline (sea)","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002398322,0.001508719,0.002594146,0.0002839362,0.000264927,0.001152839,0.0007130108,0.001026362,0.002708038],"category_scores_gemma":[0.001693324,0.0004437378,0.001794921,0.0003543056,0.0006412232,0.0006558976,0.0005299455,0.002839528,0.0003917475],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005174367,"about_ca_system_score_gemma":0.0005982963,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007092221,"about_ca_topic_score_gemma":0.001521695,"domain_scores_codex":[0.9991409,0.0005461971,0.00005477335,0.0001189743,0.00005844176,0.00008072958],"domain_scores_gemma":[0.9990622,0.0002511479,0.0002811151,0.0001043989,0.00004868798,0.0002523912],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9693974,0.002432588,0.009041237,0.0004952528,0.003579333,0.00003789956,0.0000418772,0.0004625953,0.001650882,0.0001813466,0.001333853,0.0113458],"study_design_scores_gemma":[0.9012658,0.0466143,0.04095854,0.00017854,0.00660318,0.00007838004,0.00007755899,0.001487798,0.0007358624,0.0004882389,0.001464977,0.00004684376],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985934,0.008437704,0.0002611703,0.0008460406,0.0003169261,0.0005706605,0.001245069,0.00004052265,0.002347979],"genre_scores_gemma":[0.9896203,0.002802353,0.0007361842,0.001184003,0.0005216919,0.001042251,0.002093508,0.0000154256,0.00198426],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002708038,"threshold_uncertainty_score":0.01268369,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04734247871768454,"score_gpt":0.3188666813549959,"score_spread":0.2715242026373113,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}